Thus far, ZIKV has proved an effective adjuvant to both immune checkpoint blockade (PD-1 and PD-L1) and vaccine-based immunotherapy to combat glioma and improve survival in mouse models [21–23]. This evidence concerns the gene CD274 and central nervous system cancer.